©The Author(s) 2022.
World J Gastrointest Oncol. Sep 15, 2022; 14(9): 1758-1770
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1758
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1758
Table 2 Outcomes and adverse events of endoscopic debulking resection and chemoradiotherapy
| Procedure details and outcomes of EdR | |
| Technical success, n (%) | |
| Success | 41 (100) |
| Failure | 0 (0) |
| R0 resection, n (%) | |
| Yes | 10 (24.4) |
| No | 31 (75.6) |
| Procedure time [mean ± SD (range), min] | 65 ± 29 (25-150) |
| Intraoperative complications, n (%) | |
| Mild subcutaneous emphysema | 1 (2.4) |
| None | 40 (97.6) |
| Post-operative complications, n (%) | |
| Delayed bleeding | 2 (4.9) |
| Esophageal stenosis | 19 (46.3) |
| Tracheoesophageal fistula | 2 (4.9) |
| None | 18 (43.9) |
| Complications of CRT after EdR, n (%) | |
| Myelosuppression | 7 (25) |
| Radiation pneumonia | 3 (10.7) |
| Mucous toxicity | 3 (10.7) |
| None | 15 (53.6) |
| Follow-up period [median (range), mo] | 36 (1-83) |
- Citation: Ren LH, Zhu Y, Chen R, Shrestha Sachin M, Lu Q, Xie WH, Lu T, Wei XY, Shi RH. Endoscopic debulking resection with additive chemoradiotherapy: Optimal management of advanced inoperable esophageal squamous cell carcinoma. World J Gastrointest Oncol 2022; 14(9): 1758-1770
- URL: https://www.wjgnet.com/1948-5204/full/v14/i9/1758.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i9.1758